The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age. Selected Safety Information for Rot...
n.pl.ro·ta·vi·rus·es Any of a genus of wheel-shaped reoviruses, including one that causes gastroenteritis, especially in infants and newborn animals. [New LatinRotavīrus,genus name: Latinrota,wheel; seeret-inIndo-European roots+virus.] ...
This vaccine is given by mouth by a health care professional, usually in 2 or 3 separate doses (depending on the brand). The doses are given at least 4 to 10 weeks apart. For the best protection, it is important to receive all scheduled doses. This vaccine is usually given at the ...
RotaTeq is a live, oral pentavalent vaccine that contains 5 live reassortant rotaviruses. The rotavirus parent strains of the reassortants were isolated from human andbovinehosts. Four reassortant rotaviruses express one of the outer capsid proteins (G1, G2, G3, or G4) from the human rotavi...
They were followed until: one year old, study end (December 31, 2007) or disenrollment from the health plan.ResultsMedian age at first dose for the 93,756 infants who had received DTaP and for the 48,586 infants who had received RotaTeq was 9 weeks; median age at doses 2 and 3 ...
301 healthy infants 6 to 12 week-old were enrolled in 11 countries in the Rotavirus Efficacy and Safety Trial (REST) to receive three oral doses of the pentavalent rotavirus vaccine, RotaTeq, containing the five most common human rotavirus serotypes G1, G2, G3, G4, and P1A, or ...
Similarly, no increased risk of intussusception was observed in any risk window after dose 2 or 3. CONCLUSIONS. RotaTeq vaccination was not associated with increased risk of intussusception in this analysis from 5 African countries. This finding mirrors results from similar analyses with other ...
In Analysis A, RV5 reduced the rates of combined hospitalizations and ED visits for G1鈥揋4 RVGE or RVGE regardless of serotype between doses 1 and 2 by 100% (95% confidence interval [CI]: 72鈥%) or 82% (95% CI: 39鈥), respectively, and between doses 2 and 3, RV5 reduced ...
1308 Infants were randomized 1:1 to receive 3 doses of PRV/placebo at approximately 6, 10, and 14 weeks of age. HIV counseling and testing were offered to all participants. A positive PCR result indicated HIV infection; the presence of HIV antibody in PCR-negative children indicated HIV ...
Sensitivity analyses were conducted to vary assumptions of reporting completeness and the proportion of distributed doses administered.A total of 39 reports were received, most from the US. 32 reports were confounded by concomitant administration of vaccines or medications. Median age of patient was 3...